Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00460941 · ClinicalTrials.gov registry record · Phase 2
A Titration Study of a Glucagon-Like Peptide-1 (GLP-1) Analogue in Patients With Type 2 Diabetes Treated With Metformin.
A Phase 2 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 2
- Development phase
- 133
- Enrollment target
NCT00460941 is a Phase 2 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 133 participants.
The verdict
NCT00460941, a Phase 2 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 133 participants
- Enrollment target
Study Summary
This 4 arm study will evaluate the tolerability, efficacy and pharmacodynamics of different doses of a GLP-1 analogue in patients with type 2 diabetes who are treated with a stable dose of metformin. Patients will be randomized to receive either subcutaneous placebo, or subcutaneous GLP-1 analogue (at a dose of 20mg, or a starting dose of 20mg escalating to either 30mg or 40mg), weekly. All patients will continue on their existing metformin treatment regimen throughout the study. The anticipated time on study treatment is \<3 months, and the target sample size is 100-500 individuals.
Interventions
- DRUG Placebo
- DRUG Taspoglutide 20mg
- DRUG Taspoglutide 20mg-30mg
- DRUG Taspoglutide 20mg-40mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 133 participants |
| Start Date | 2007-04 |
| Est. Completion | 2008-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00460941
The ClinicalTrials.gov registry entry for NCT00460941 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 133 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00460941 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00460941 about?
NCT00460941 is a clinical study titled "A Titration Study of a Glucagon-Like Peptide-1 (GLP-1) Analogue in Patients With Type 2 Diabetes Treated With Metformin.". This 4 arm study will evaluate the tolerability, efficacy and pharmacodynamics of different doses of a GLP-1 analogue in patients with type 2 diabetes who are treated with a stable dose of metformin. Patients will be randomized to receive either subcutaneous placebo, or subcutaneous GLP-1 analogue (...
What is the current status of trial NCT00460941?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 133 participants. The study started on 2007-04. Estimated completion is 2008-01.
What interventions are being tested in trial NCT00460941?
The interventions under investigation include: Placebo (DRUG), Taspoglutide 20mg (DRUG), Taspoglutide 20mg-30mg (DRUG), Taspoglutide 20mg-40mg (DRUG).
Who is sponsoring clinical trial NCT00460941?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.